Systematic assessment of pharmaceutical prescriptions in association with cancer risk : a method to conduct a population-wide medication-wide longitudinal study
Patel, Chirag J. LU ; Ji, Jianguang LU
; Sundquist, Jan
LU
; Ioannidis, John P A
and Sundquist, Kristina
LU
(2016)
In Scientific Reports
6.
- Abstract
It is a public health priority to identify the adverse and non-adverse associations between pharmaceutical medications and cancer. We search for and evaluate associations between all prescribed medications and longitudinal cancer risk in participants of the Swedish Cancer Register (N = 9,014,975). We associated 552 different medications with incident cancer risk (any, breast, colon, and prostate) during 5.5 years of follow-up (7/1/2005-12/31/2010) in two types of statistical models, time-to-event and case-crossover. After multiple hypotheses correction and replication, 141 (26%) drugs were associated with any cancer in a time-to-event analysis constraining drug exposure to 1 year before first cancer diagnosis and adjusting for history... (More)
It is a public health priority to identify the adverse and non-adverse associations between pharmaceutical medications and cancer. We search for and evaluate associations between all prescribed medications and longitudinal cancer risk in participants of the Swedish Cancer Register (N = 9,014,975). We associated 552 different medications with incident cancer risk (any, breast, colon, and prostate) during 5.5 years of follow-up (7/1/2005-12/31/2010) in two types of statistical models, time-to-event and case-crossover. After multiple hypotheses correction and replication, 141 (26%) drugs were associated with any cancer in a time-to-event analysis constraining drug exposure to 1 year before first cancer diagnosis and adjusting for history of medication use. In a case-crossover analysis, 36 drugs (7%) were associated with decreased cancer risk. 12 drugs were found in common in both analyses with concordant direction of association. We found 14, 10, 7% of all drugs associated with colon, prostate, and breast cancers in time-to-event models. We only found 1, 2%, and 0% for these cancers, respectively, in case-crossover analyses. Pharmacoepidemiologic analyses of cancer risk are sensitive to modeling choices and false-positive findings are a threat. Medication-wide analyses using different analytical models may help suggest consistent signals of increased cancer risk.
(Less)
- author
- Patel, Chirag J.
LU
; Ji, Jianguang
LU
; Sundquist, Jan
LU
; Ioannidis, John P A
and Sundquist, Kristina
LU
- organization
- publishing date
- 2016-08-10
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Scientific Reports
- volume
- 6
- article number
- 31308
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:27507038
- wos:000381107400001
- scopus:84981719896
- ISSN
- 2045-2322
- DOI
- 10.1038/srep31308
- language
- English
- LU publication?
- yes
- id
- 4d4067d9-387f-4f2e-b124-3e064f34e8bb
- date added to LUP
- 2016-12-07 12:18:15
- date last changed
- 2025-10-14 12:39:49
@article{4d4067d9-387f-4f2e-b124-3e064f34e8bb,
abstract = {{<p>It is a public health priority to identify the adverse and non-adverse associations between pharmaceutical medications and cancer. We search for and evaluate associations between all prescribed medications and longitudinal cancer risk in participants of the Swedish Cancer Register (N = 9,014,975). We associated 552 different medications with incident cancer risk (any, breast, colon, and prostate) during 5.5 years of follow-up (7/1/2005-12/31/2010) in two types of statistical models, time-to-event and case-crossover. After multiple hypotheses correction and replication, 141 (26%) drugs were associated with any cancer in a time-to-event analysis constraining drug exposure to 1 year before first cancer diagnosis and adjusting for history of medication use. In a case-crossover analysis, 36 drugs (7%) were associated with decreased cancer risk. 12 drugs were found in common in both analyses with concordant direction of association. We found 14, 10, 7% of all drugs associated with colon, prostate, and breast cancers in time-to-event models. We only found 1, 2%, and 0% for these cancers, respectively, in case-crossover analyses. Pharmacoepidemiologic analyses of cancer risk are sensitive to modeling choices and false-positive findings are a threat. Medication-wide analyses using different analytical models may help suggest consistent signals of increased cancer risk.</p>}},
author = {{Patel, Chirag J. and Ji, Jianguang and Sundquist, Jan and Ioannidis, John P A and Sundquist, Kristina}},
issn = {{2045-2322}},
language = {{eng}},
month = {{08}},
publisher = {{Nature Publishing Group}},
series = {{Scientific Reports}},
title = {{Systematic assessment of pharmaceutical prescriptions in association with cancer risk : a method to conduct a population-wide medication-wide longitudinal study}},
url = {{http://dx.doi.org/10.1038/srep31308}},
doi = {{10.1038/srep31308}},
volume = {{6}},
year = {{2016}},
}